Abstract
Resistant hypertension (RH) is a prevalent medical problem across all ages but is more frequent in elderly patients. This entity has to be distinguished from clinical settings which may simulate it such as apparent hypertension (pseudohypertension) or apparently resistant hypertension (pseudoresistant hypertension) [1]. An appropriate therapy for RH can be achieved by the addition of second line antihypertensive drugs: antialdosteronic diuretics, central agents, alpha blockers, direct vasodilating agents, and exogenous nitric oxide donors. These antihypertensive drugs are considered as second line drugs since they are less effective as monotherapy to reduce blood pressure (they induce counte regulatory responses that limit their antihypertensive effect such as volume expansion or reflex tachycardia) and prevent cardiovascular events, or due to significant adverse effects (postural hypotension, sedation, hyperkalemia). Second line drugs are also used when there is allergy or intolerance to the first line ones [2, 3].
Keywords: Hypertension, elderly, aldosterone, vasodilators, nitric oxide.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Volume: 12 Issue: 3
Author(s): Carlos G. Musso and Jose Alfie
Affiliation:
Keywords: Hypertension, elderly, aldosterone, vasodilators, nitric oxide.
Abstract: Resistant hypertension (RH) is a prevalent medical problem across all ages but is more frequent in elderly patients. This entity has to be distinguished from clinical settings which may simulate it such as apparent hypertension (pseudohypertension) or apparently resistant hypertension (pseudoresistant hypertension) [1]. An appropriate therapy for RH can be achieved by the addition of second line antihypertensive drugs: antialdosteronic diuretics, central agents, alpha blockers, direct vasodilating agents, and exogenous nitric oxide donors. These antihypertensive drugs are considered as second line drugs since they are less effective as monotherapy to reduce blood pressure (they induce counte regulatory responses that limit their antihypertensive effect such as volume expansion or reflex tachycardia) and prevent cardiovascular events, or due to significant adverse effects (postural hypotension, sedation, hyperkalemia). Second line drugs are also used when there is allergy or intolerance to the first line ones [2, 3].
Export Options
About this article
Cite this article as:
Musso Carlos G. and Alfie Jose, Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (3) . https://dx.doi.org/10.2174/1871525713666150310110934
DOI https://dx.doi.org/10.2174/1871525713666150310110934 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Infant Breast-Feeding and Suppression of Biomarkers of Future Cardiovascular Disease
Current Nutrition & Food Science Synthesis, Molecular Modeling of Novel Substituted Pyridazinones and their Vasorelaxant Activities
Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Subject Index To Volume 2
Current Cardiology Reviews Central Blood Pressure and Prediction of Cardiovascular Events
Current Hypertension Reviews Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS) Dilemmas in Diagnosis & Treatment
Current Women`s Health Reviews Syntheses and Biological Activities of triazole-based Sulfonamides
Current Organic Chemistry 3-(1H-Pyrrol-2-yl)-2-oxazolidinones as Novel Monoamine Oxidase Type A Inhibitors
Medicinal Chemistry Synthesis and Antithrombotic Activity Study of Some New Thienopyridine Derivatives
Letters in Organic Chemistry Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Design and Optimization of Chronotherapeutic Dosage Form for the Treatment of Angina Pectoris
Drug Delivery Letters Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Current Cardiology Reviews Steroid Hormones and Sleep Regulation
Mini-Reviews in Medicinal Chemistry Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Patent Selections
Recent Patents on Anti-Infective Drug Discovery Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets